Home > Insider Trading > Filing (0001181431-12-042342)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1544116	Durata Therapeutics Inc.	DRTX	Pharmaceutical Preparations (2834)	871247903

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1247851	Ronald Hunt	C/O New Leaf Ventures Times Square Tower, 7 Times Sq, Ste 3502 New York NY 10036		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-07-24	2,244,126	$0.00	2,244,126	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2012-07-24	784,313	$9.00	3,028,439	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2012-07-24	17,953,008	$0.00	2,244,126	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect

Footnotes

All outstanding shares of Series A Preferred Stock were automatically converted into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration.
The securities are directly held by New Leaf Ventures II, L.P. ("NLV II") and indirectly held by New Leaf Venture Associates II, L.P. ("NLV Associates II"), the sole general partner of NLV II, and New Leaf Venture Management II, L.L.C. ("NLV Management II"), the sole general partner of NLV Associates II. Ronald Hunt ("Hunt"), in his capacity as a manager of NLV Management II, may be deemed to beneficially own the shares to which this Form 4 relates. Hunt disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.